- Home
- BWIN vs PTGX Comparison
BWIN vs PTGX Comparison
Compare BWIN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- PTGX
- Stock Information
- Founded
- BWIN 2011
- PTGX 2006
- Country
- BWIN United States
- PTGX United States
- Employees
- BWIN N/A
- PTGX N/A
- Industry
- BWIN Specialty Insurers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- BWIN Finance
- PTGX Health Care
- Exchange
- BWIN Nasdaq
- PTGX Nasdaq
- Market Cap
- BWIN 2.9B
- PTGX 2.4B
- IPO Year
- BWIN 2019
- PTGX 2016
- Fundamental
- Price
- BWIN $44.69
- PTGX $48.36
- Analyst Decision
- BWIN Buy
- PTGX Strong Buy
- Analyst Count
- BWIN 8
- PTGX 8
- Target Price
- BWIN $44.43
- PTGX $66.50
- AVG Volume (30 Days)
- BWIN 685.6K
- PTGX 1.6M
- Earning Date
- BWIN 05-06-2025
- PTGX 05-06-2025
- Dividend Yield
- BWIN N/A
- PTGX N/A
- EPS Growth
- BWIN N/A
- PTGX N/A
- EPS
- BWIN N/A
- PTGX 4.23
- Revenue
- BWIN $1,389,037,000.00
- PTGX $434,433,000.00
- Revenue This Year
- BWIN $13.39
- PTGX N/A
- Revenue Next Year
- BWIN $13.65
- PTGX $8.12
- P/E Ratio
- BWIN N/A
- PTGX $11.43
- Revenue Growth
- BWIN 13.99
- PTGX 624.05
- 52 Week Low
- BWIN $26.08
- PTGX $24.22
- 52 Week High
- BWIN $55.82
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- BWIN 58.50
- PTGX 51.52
- Support Level
- BWIN $44.04
- PTGX $51.06
- Resistance Level
- BWIN $46.57
- PTGX $53.70
- Average True Range (ATR)
- BWIN 1.80
- PTGX 2.27
- MACD
- BWIN 0.40
- PTGX -0.94
- Stochastic Oscillator
- BWIN 70.61
- PTGX 9.41
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.